ES2187753T3 - Procedimiento para la preparacion de d-treo-(r;r)-metilfenidato y para el reciclaje de enantiomeros no deseados mediante epimerizacion. - Google Patents

Procedimiento para la preparacion de d-treo-(r;r)-metilfenidato y para el reciclaje de enantiomeros no deseados mediante epimerizacion.

Info

Publication number
ES2187753T3
ES2187753T3 ES97902435T ES97902435T ES2187753T3 ES 2187753 T3 ES2187753 T3 ES 2187753T3 ES 97902435 T ES97902435 T ES 97902435T ES 97902435 T ES97902435 T ES 97902435T ES 2187753 T3 ES2187753 T3 ES 2187753T3
Authority
ES
Spain
Prior art keywords
treo
methylphenidate
unantiomers
epimerization
unwanted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97902435T
Other languages
English (en)
Inventor
Marianne Langston
Hooshang Shahriari Zavareh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602174.6A external-priority patent/GB9602174D0/en
Priority claimed from GBGB9618836.2A external-priority patent/GB9618836D0/en
Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd
Application granted granted Critical
Publication of ES2187753T3 publication Critical patent/ES2187753T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UN PROCESO PARA LA OBTENCION DE UN SOLO ENANTIOMERO, D O L, DE TREO - METILFENIDATO, QUE COMPRENDE UNA RESOLUCION DE UNA MEZCLA DE LOS ENANTIOMEROS; LA RACEMIZACION DEL ENANTIOMERO NO DESEADO, PARA OBTENER UNA MEZCLA DE LOS CUATRO ESTEREOISOMEROS; Y EN LA SEPARACION DE LOS ERITRO ESTEREOISOMEROS; PARA DEJAR LA MEZCLA DE ENANTIOMEROS ANTEDICHA PARA SU RESOLUCION.
ES97902435T 1996-02-02 1997-01-31 Procedimiento para la preparacion de d-treo-(r;r)-metilfenidato y para el reciclaje de enantiomeros no deseados mediante epimerizacion. Expired - Lifetime ES2187753T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9602174.6A GB9602174D0 (en) 1996-02-02 1996-02-02 Resolution/racemization process
GBGB9618836.2A GB9618836D0 (en) 1996-09-10 1996-09-10 Resolution/racemisation process

Publications (1)

Publication Number Publication Date
ES2187753T3 true ES2187753T3 (es) 2003-06-16

Family

ID=26308593

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97902435T Expired - Lifetime ES2187753T3 (es) 1996-02-02 1997-01-31 Procedimiento para la preparacion de d-treo-(r;r)-metilfenidato y para el reciclaje de enantiomeros no deseados mediante epimerizacion.

Country Status (16)

Country Link
US (1) US7164025B2 (es)
EP (1) EP0879228B1 (es)
JP (1) JP2000504008A (es)
KR (1) KR100453707B1 (es)
AT (1) ATE226940T1 (es)
AU (1) AU715183B2 (es)
CA (1) CA2243534C (es)
CZ (1) CZ292609B6 (es)
DE (1) DE69716713T2 (es)
DK (1) DK0879228T3 (es)
ES (1) ES2187753T3 (es)
HU (1) HUP9901658A3 (es)
MX (1) MX209701B (es)
PT (1) PT879228E (es)
SK (1) SK283553B6 (es)
WO (1) WO1997028124A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
GB9700912D0 (en) * 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
JP2008523097A (ja) * 2004-12-09 2008-07-03 セルジーン・コーポレーション Ｄ−トレオメチルフェニデートを用いた治療
US7897777B2 (en) * 2007-01-05 2011-03-01 Archimica, Inc. Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
BR112013024401B1 (pt) 2011-03-23 2022-01-11 Ironshore Pharmaceuticals & Development, Inc Composição farmacêutica sólida oral compreendendo um ingrediente ativo estimulante do sistema nervoso central e o uso terapêutico da mesma
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP3897594B1 (en) 2018-12-19 2024-07-10 The General Hospital Corporation Dextroamphetamine and lisdexamfetamine to reverse dexmedetomidine sedation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
SU466229A1 (ru) * 1973-01-23 1975-04-05 Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе Способ получени гидрохлорида метилового эфира трео- -фенил- (пиперидил-2)-уксусной кислоты
US4254261A (en) * 1979-10-15 1981-03-03 Merck & Co., Inc. Dehydroabietylammonium salts of 6-oxo-2-piperidinecarboxylic acid
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
MX9805870A (es) * 1996-01-22 1999-01-31
US6242464B1 (en) * 1996-01-22 2001-06-05 Chiroscience Limited Single isomer methylphenidate and resolution process
GB9604943D0 (en) * 1996-03-08 1996-05-08 Chiroscience Ltd Resolution

Also Published As

Publication number Publication date
MX9806209A (es) 1998-10-31
ATE226940T1 (de) 2002-11-15
EP0879228B1 (en) 2002-10-30
CZ292609B6 (cs) 2003-11-12
SK283553B6 (sk) 2003-09-11
US7164025B2 (en) 2007-01-16
CA2243534C (en) 2003-08-26
WO1997028124A1 (en) 1997-08-07
HUP9901658A2 (hu) 1999-09-28
AU1608297A (en) 1997-08-22
CZ227598A3 (cs) 1998-12-16
DE69716713D1 (de) 2002-12-05
KR19990082186A (ko) 1999-11-25
US20020032335A1 (en) 2002-03-14
KR100453707B1 (ko) 2005-01-25
CA2243534A1 (en) 1997-08-07
SK97998A3 (en) 1999-01-11
PT879228E (pt) 2003-01-31
DK0879228T3 (da) 2003-03-03
EP0879228A1 (en) 1998-11-25
DE69716713T2 (de) 2003-07-03
MX209701B (es) 2002-08-15
HUP9901658A3 (en) 1999-12-28
JP2000504008A (ja) 2000-04-04
AU715183B2 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
ES2124053T3 (es) Procedimiento integrado para la produccion de buteno-1.
DK0879228T3 (da) Fremgangsmåde til fremstilling af d-threo-(R,R)-methylphenidat og recirkulering af uønskede enantiomerer ved epimerisering
DE69312402D1 (de) Feststoffgenerator zur Herstellung von Sauerstoff unter hohem Druck
ES2143558T3 (es) Agentes policiclicos antiparasitarios, procedimiento y cepa para su preparacion y su uso.
MX9201139A (es) Nuevos esteres de amino alcoholes bi- y triciclicos, procedimiento para su reparacion y composiciones farmaceuticas que los c0ntienen.
NO975387L (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
ES2150567T3 (es) Antagonistas del factor de liberacion de la corticotropina.
PA8464901A1 (es) Procesos para la sintesis de 1,3-dioles
ES2101063T3 (es) Derivados monofluorados de n-propargil-1-amino-indano y su utilizacion como inhibidores de la monoamin-oxidasa.
ES2079490T3 (es) Procedimiento para preparar dispersiones acuosas.
ES2162954T3 (es) Procedimiento para la produccion de derivados de purina.
UA66769C2 (uk) Спосіб одержання метопрололу
ES2115820T3 (es) Procedimiento y maquina de fabricacion de neumaticos.
AR002721A1 (es) Proceso para preparar 2- metil-4-(4-metil-1-piperacinil)-10h-tieno [2,3-b][1,5]benzodiacepina(olanzapina) que contiene menos de 5 % de substancias relacionadas indeseables
ES2066931T3 (es) Procedimiento para la inversion estereoquimica de los (2s,3s)-2-amino-3-fenil-1,3-propanodioles en sus (2r,3r)-enantiomeros.
FR2364891A1 (fr) Procede d'isomerisation des stereoisomeres de diamines cycloaliphatiques
FR2389625A1 (es)
ES2097509T3 (es) Procedimiento para la fabricacion de hexafluoroclorobutenos.
ES2126279T3 (es) Nuevos tetrapeptidos su obtencion y empleo.
ES2096198T3 (es) Procedimiento para separar componentes coloreados a partir de un disolvente para poliacrilonitrilo.
ES2118389T3 (es) Procedimiento para un tratamiento electroquimico de lejia residual de celulosa.
ES2139714T3 (es) Fluororribosil-aminas anomericas.
AR015771A1 (es) Proceso para la preparacion de r-(+)-6-carboxamido-3-n-metilamino-1,2,3,4-tetrahidrocarbazol, compuestos intermediarios y el uso del acido l-piroglutamico.
MX9304608A (es) Nuevas (n-metanosulfonil)-quinolilmetoxifenil-cicoalquilacetamidas sustituidas por isobutilo, procedimiento para su preparacion y medicamentos que las contienen.
JPS5226012A (en) Metallic cylinder of multiplex materials and its manufacturing process